Medical Condition News

RSS

SSA to add early-onset Alzheimer's disease to its Compassionate Allowances Initiative

In its effort to improve and expedite the disability determination process, the Social Security Administration has announced that it will add early-onset Alzheimer's disease to its Compassionate Allowances Initiative. The initiative identifies debilitating diseases and medical conditions that meet the SSA's disability standards for Social Security Disability Income (SSDI) or Supplemental Security Income (SSI).

12 Feb 2010

Clinical research study conducted for patients with IC/PBS

A clinical research study is being conducted for patients with Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS), a chronic bladder disorder characterized by intense pelvic pain, urinary frequency-urgency, and pain during sexual intimacy (www.PainfulBladderStudy.org). It is estimated that as many as 1.3 million people in the U.S. have been diagnosed with this disease and many more remain undiagnosed.

12 Feb 2010

Mediterranean diet beneficial to heart health: Study

In countries bordering the Mediterranean Sea, heart disease is less common than in the United States. Researchers believe that foods common to Greece and southern Italy are a major reason for this difference.

12 Feb 2010

Social Security Administration adds early-onset Alzheimer's disease to Compassionate Allowances list: AFA lauds

The Alzheimer's Foundation of America (AFA) today applauded the Social Security Administration for including early-onset Alzheimer's disease among the medical conditions that will be given automatic approval for disability benefits, rather than have individuals go through what could be a lengthy qualification process.

12 Feb 2010

OrbusNeich commences enrollment in Chinese Genous Bio-engineered R stent trial

OrbusNeich today announced that the first patient has been enrolled in a randomized clinical trial of the Genous Bio-engineered R stent in China.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

Researchers identify potential drug candidate that halts tumor growth

A novel - and rapid - anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic tumors from growing in mice. Researchers at the Moores Cancer Center at the University of California, San Diego, have found a drug that binds to a molecular "switch" found in cancer cells and cancer-associated blood vessels to keep it in the "off" position.

12 Feb 2010

Cancer drug could be effective for treating recurrent nose bleeds

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin.

12 Feb 2010

Study could lead to new ways to combat obesity

The tiny tongue of a fruit fly could provide big answers to questions about human eating habits, possibly even leading to new ways to treat obesity, according to a study from a team of Texas A&M University researchers.

12 Feb 2010

Blood test to detect elevated levels of antibodies unique to Alzheimer’s disease developed

OPKO Health, Inc. today announced the development of a simple diagnostic blood test for Alzheimer’s disease. The test, designed to detect elevated levels of antibodies unique to Alzheimer’s disease, was approximately 95% accurate in initial testing.

12 Feb 2010

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).

12 Feb 2010

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."

12 Feb 2010

Researchers discover cancer gene in ancestral metazoan

To find the causes for cancer, biochemists and developmental biologists at the University of Innsbruck, Austria, retraced the function of an important human cancer gene 600 million years back in time. For the first time, they have identified the oncogene myc in a fresh water polyp and they have shown that this oncogene has similar biochemical functions in ancestral metazoan and in humans.

12 Feb 2010

New amplitude gating technique helps scanners pinpoint tumors

When one diagnoses a cancer patient, it's important to gather as much information about that person as possible. But who would have thought an accurate diagnosis would depend on throwing some of that information away?

12 Feb 2010

Scientists uncover new gene that could help save sight of patients with inherited blindness

The international research team led by the University of Leeds found that the TSPAN12 gene is faulty in patients with a disease known as FEVR (Familial Exudative Vitreoretinopathy), which affects the development of the eye.

12 Feb 2010

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.

12 Feb 2010

FKF receives funds to launch Fragile Kids Partner Program

The Centene Foundation for Quality Healthcare announced today that it has awarded a $35,000 grant to Fragile Kids Foundation, Inc. (FKF), a nonprofit organization based in Atlanta, Ga.

12 Feb 2010

British rhubarb could be a potential source of anti-cancer agent

Eating rhubarb baked in a crumble is not only tasty it may also be the best way to take advantage of its health benefits, and could lead to the development of new cancer treatments.

From Sheffield Hallam University 11 Feb 2010

Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics announced today additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida.

11 Feb 2010

Critical phases of brain development may be mistimed in autistic patients, says study

Research into Fragile X Syndrome - a genetic condition that is the leading known cause of autism - has discovered that critical phases in the brain's development may be mistimed in people with the condition.

11 Feb 2010

Medical Condition News

SSA to add early-onset Alzheimer's disease to its Compassionate Allowances Initiative

Clinical research study conducted for patients with IC/PBS

Mediterranean diet beneficial to heart health: Study

Social Security Administration adds early-onset Alzheimer's disease to Compassionate Allowances list: AFA lauds

OrbusNeich commences enrollment in Chinese Genous Bio-engineered R stent trial

Second-quarter fiscal 2010 results announced by Pharmacyclics

Researchers identify potential drug candidate that halts tumor growth

Cancer drug could be effective for treating recurrent nose bleeds

Study could lead to new ways to combat obesity

Blood test to detect elevated levels of antibodies unique to Alzheimer’s disease developed

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Researchers discover cancer gene in ancestral metazoan

New amplitude gating technique helps scanners pinpoint tumors

Scientists uncover new gene that could help save sight of patients with inherited blindness

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

FKF receives funds to launch Fragile Kids Partner Program

British rhubarb could be a potential source of anti-cancer agent

Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

Critical phases of brain development may be mistimed in autistic patients, says study

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News